A. Menarini Diagnostics has launched its new PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR.
The COVID-19 pandemic has significantly reshaped the molecular diagnostics market, pushing it in the direction of seamless automation, ease-of-use, fast turnaround times and test reliability. In spite of the significant advances in the domain, several testing applications still rely on laboratory-developed tests and labour-intensive techniques which make the implementation of large-scale automated diagnostics solutions inconvenient.
In response to these needs and market dynamics, A.Menarini Diagnostics rose to the challenge and coordinated the development of a brand new solution, relying on the skills of its R&D department with Italian and international partners.
PRIME MDx allows users to process a range of sample types thanks to the clever adoption of pre-filled plates together with universal extraction solution, running up to five different assays per sample for a maximum capacity of 240 samples per day.
The AI-driven software ensures a flawless customer experience, from continuous sample loading to result interpretation.
The system will be launched on the market with two panels of tests, one for viral upper respiratory-tract infections and one for viral transplant infections on a broad spectrum of sample matrices. Other testing panels are currently in development to complete the offer.
"We are proud to bring this innovative, all-in-one, molecular diagnostics solution to the market, which will allow us to address the needs of medium- to high-throughput laboratories internationally and strengthen the position of A. Menarini Diagnostics in the molecular space," commented Fabio Piazzalunga, General Manager and Global Head of Diagnostics Division in Menarini Group.